Follow us

Open Orphan (ORPH)

Open Orphan (ORPH) presentation at ShareSoc March 2020

16 March 2020

By Cathal Friel, Exec Chair

Friel gives an overview of Open Orphan, how it was formed, the business, hVIVO and its work with virus testing, plus comments on COVID-19.

Introduction – 00:18
Open Orphan management – 03:00
History and acquisitions – 04:15
High value & longer-term contracts – 08:32
Open Orphan – 09:22
Genomic database – 10:13
hVIVO viral challenge studies, etc – 10:33
Cross-selling – 17:45
Pipeline – 18:42
Cost reduction programme – 19:42
Development assets – 20:01
COVID-19 – 21:12

Q&A – 29:15

Open Orphan plc, formerly Venn Life Sciences Holdings plc, is engaged in the pharma services business. The Company is also engaged in building an orphan drug consulting services platform that helps pharma companies commercialize their products in Europe. The Company consists of four elements: a European clinical research organization and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians, and a Health Data Platform. The Company provides fragmented orphan drug services. The Company acquires and consolidates series of orphan drug services companies. It also provides digital data platforms to support companies in research & development and commercialization.


Listen on the go


PIWORLD provides investors with the latest news and insight about listed companies and their management through either live or recorded investor presentations, management interviews, Capital Market Days and corporate overviews, together with interviews with leading fund managers or esteemed private investors in the small cap world.

Our Services

PIWORLD delivers high quality audio and video content to present anything from full-year & interim results to Capital Markets Days and corporate overviews. We bridge the gap between listed companies and the private investor community, who drive the share price and provide liquidity, providing a time and cost effective medium to reach this diverse and important audience.